Screener
Nektar Therapeutics NKTR Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $10.13M-9.3% | $10.86M+3.8% | $21.81M-25.3% | $11.79M-51.1% | $11.18M-52.4% | ||
| —— | —— | $21.81M+2.9% | $11.79M-40.1% | $11.18M-18.7% | ||
| $39.13M+30.9% | $35.68M+17.1% | $29.71M+3.4% | $27.25M-22.2% | $29.89M+0.5% | ||
| $12.77M-25.2% | $13.44M-44.8% | $11.19M-34.7% | $16.07M-15.2% | $17.07M-16.8% | ||
| $52.47M+10.7% | $49.92M-9.2% | $49.47M+234% | $43.46M-25.7% | $47.41M-35.3% | ||
| -$42.34M-16.9% | -$39.05M+12.3% | -$27.67M— | -$31.67M+7.8% | -$36.23M+27.2% | ||
| -417.9%-93.7pp | -359.6%+66.2pp | -126.9%— | -268.6%-126pp | -324.2%-112pp | ||
| $2.04M+164% | -$4.04M-120% | -$7.04M+4.2% | -$3.35M-23.9% | -$3.17M-24.5% | ||
| -$40.3M-2.3% | -$43.09M+7.1% | -$34.7M— | -$35.02M+5.5% | -$39.4M+24.7% | ||
| $2K+101% | $64K+23.1% | —— | -$33K-467% | -$188K-509% | ||
| -$40.62M+2.3% | -$44.9M+11.7% | -$36.08M— | -$35.52M+4.1% | -$41.59M+20.6% | ||
| -401%-28.8pp | -413.4%+73.0pp | -165.4%-165pp | -301.3%-148pp | -372.2%-149pp | ||
| -$1.23+58.3% | -$1.82+49.7% | -$1.59+23.2% | -$1.87+29.7% | -$2.95+21.5% | ||
| -$42.19M-17.1% | -$38.9M+11.8% | -$27.48M-8,376% | -$31.48M+5.6% | -$36.02M+25.5% | ||
| -416.4%-94.1pp | -358.2%+63.5pp | -126%-127pp | -267%-129pp | -322.3%-117pp | ||
| -$42.34M-16.9% | -$39.05M+12.3% | -$27.67M— | -$31.67M+7.8% | -$36.23M+27.2% |
FAQ
- What is Nektar Therapeutics's revenue?
- Nektar Therapeutics (NKTR) generated $54.6M in revenue over the trailing twelve months, down 27.2% year over year.
- Is Nektar Therapeutics profitable?
- Nektar Therapeutics is not currently profitable: it reported a net loss of $157.1M over the trailing twelve months, a -287.8% net margin.
- What are Nektar Therapeutics's profit margins?
- Gross margin is 100.0% and operating margin is -257.8%, with a -287.8% net margin.
- What is Nektar Therapeutics's earnings per share?
- Nektar Therapeutics's diluted EPS over the trailing twelve months is $-6.51.
- Where does Nektar Therapeutics's income statement data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
